Thierry Andre

Thierry Andre led the KEYNOTE-177 trial and is a key investigator in the IDEA collaboration examining optimal duration of adjuvant FOLFOX or CAPOX in stage III colon cancer. His work on MSI-H/dMMR colorectal cancer has established pembrolizumab as a first-line standard and is investigating adjuvant pembrolizumab in dMMR colon cancer. He contributed to demonstrating both the benefit and potential harm of adjuvant immunotherapy in MSI-H versus MSS disease contexts. Andre is among the most influential researchers in colorectal cancer globally, with contributions spanning adjuvant chemotherapy to immunotherapy.